Details
Intellia said the FDA lifted the clinical hold on its heart-disease gene-editing trial for transthyretin amyloidosis, a rare condition caused by buildup of a faulty protein in organs. The restart matters because this therapy aims to change disease biology more deeply than standard chronic treatment. For patients with limited time, that kind of possibility feels huge. ❤️
Still, the pause happened for a serious reason. A patient in the heart-disease study had severe liver complications and later died, forcing the company and regulator to rethink who should be included and how people should be monitored. So the science may be advancing, but the controversy is really about how much risk is acceptable when editing genes inside the body.